Daily Positive Signals: a supernova impostor, a peanut-allergy shot, and a wallet for AI agents

On this page
  1. The star that survived 27 explosions has a hidden companion
  2. A monthly shot helps children tolerate peanuts
  3. A liver drug’s year-long results, now peer-reviewed
  4. AI agents can now pay — without seeing your card
  5. Useful progress, without the hype
  6. Know someone this would help?
  7. References

Listen to this brief · about 6 min, story text only

This edition: a giant star’s 27 explosions traced to a hidden companion; a monthly shot that helps children tolerate peanuts; a liver drug’s year-long results, now peer-reviewed; and a wallet that lets AI agents pay without seeing your card. The thread: the check behind the claim.

Signal 1 of 4 · Space

The star that survived 27 explosions has a hidden companion

27 eruptions
bright outbursts recorded since 2012, without destroying the star
113-day cycle
the companion’s orbital period, timing every outburst

Astronomers have solved a 15-year mystery: the giant star AT 2016blu, a luminous blue variable at least 33 times the Sun’s mass and 30 million light-years away, has erupted at least 27 times since 2012 without destroying itself (NASA, 2026). Using NASA’s Chandra X-ray Observatory, researchers found a hidden companion — a black hole or a neutron star — that swings past the star every 113 days and pulls gas from it (NASA, 2026). The stolen gas forms a hot disk that shines in X-rays, heating surrounding material until it glows like an explosion (NDTV, 2026). In March 2026, Chandra caught the system at least 100 times brighter in X-rays than in 2001 and 2002, before the eruptions began — the first X-rays ever detected from this kind of erupting star (NASA, 2026; NDTV, 2026).

Why it matters. Supernova impostors have puzzled astronomers for years, because a star that explodes should not survive. This one shows how a companion can stage the same show again and again — and more than 30 amateur astronomers helped time the observations that proved it.

Evidence status: Peer-reviewed study in The Astrophysical Journal, reported by NASA (November 13, 2026) and independently covered by NDTV. Limits: whether the companion is a black hole or a neutron star is still open; the mass-transfer rate strains current models of how neutron stars feed.


Signal 2 of 4 · Medicine

A monthly shot helps children tolerate peanuts

39.4% vs 16.7%
of children tolerated at least 443 mg of peanut protein, drug vs placebo
6 months
the benefit held after treatment stopped, with no new dosing

A monthly immunotherapy shot helped children with peanut allergy tolerate far more peanut, in a Phase 2 trial reported November 12 (Aravax, 2026). In the randomized, double-blind trial, 71 children aged 4 to 11 received 12 monthly doses of PVX108 or a placebo at 14 sites in the United States and Australia (Aravax, 2026). On the higher dose, the maximum tolerated dose of peanut rose 2.4-fold from baseline, against 1.2-fold on placebo, and 39.4% tolerated at least 443 milligrams of peanut protein, against 16.7% on placebo (Aravax, 2026; Pharmacally, 2026). The benefit held six months after treatment stopped, and no treatment-related anaphylaxis or serious adverse events were reported (Aravax, 2026; SnackSafely, 2026).

Why it matters. Current peanut-allergy treatments demand daily dosing and carry real reaction risk. A monthly shot that keeps working six months after the last dose would change the burden entirely — if larger trials confirm it.

Evidence status: Company-reported topline Phase 2 results (November 12, 2026), independently covered by Pharmacally and SnackSafely; full data presented at the American College of Allergy, Asthma and Immunology meeting on November 14. Limits: small cohort (71 children in the main group); peer-reviewed publication pending; PVX108 is investigational and not approved.


Signal 3 of 4 · Medicine

A liver drug’s year-long results, now peer-reviewed

32.4% vs 3.2%
hit a combined liver-stiffness and fibrosis-marker target, drug vs placebo
212 participants
with biopsy-confirmed MASH and moderate to advanced fibrosis

Pemvidutide, an investigational drug for the fatty liver disease MASH, showed continued improvement at 48 weeks in results published November 12 in The Lancet Gastroenterology & Hepatology (Altimmune, 2026). The randomized, double-blind IMPACT Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and moderate to advanced fibrosis (Altimmune, 2026). About a third of patients on the higher dose hit a combined target of lower liver stiffness and a lower fibrosis marker, against 3.2% on placebo, alongside significant weight loss (The Pharma Letter, 2026). About 1% of patients stopped treatment because of side effects, and a global Phase 3 trial is already running, with its main readout expected in 2029 (Altimmune, 2026).

Why it matters. Few drugs are approved for MASH, and fibrosis is what drives long-term outcomes. A drug that keeps improving liver measures over a full year — with weight loss and a clean tolerability record — is exactly the profile a Phase 3 trial needs to confirm.

Evidence status: Peer-reviewed 48-week results in The Lancet Gastroenterology & Hepatology (November 12, 2026), announced by Altimmune and independently covered by The Pharma Letter. Limits: the 48-week results are secondary endpoints; the primary endpoint was met at 24 weeks; pemvidutide is investigational, and Phase 3 results are years away.


Signal 4 of 4 · AI

AI agents can now pay — without seeing your card

0 card numbers shared
agents pay with single-use tokens, never the real card
1 approval per purchase
every transaction needs a biometric check from the user

OpenAI launched ChatGPT Wallet on November 13, letting AI agents complete purchases on a user’s behalf without ever seeing the user’s card details (OpenAI, 2026). Users add a card once, then approve each purchase with a biometric check such as Face ID; the payment network issues a single-use token for that transaction (OpenAI, 2026). The wallet is built with American Express, Mastercard, and Visa, and it preserves the card’s existing rewards and dispute protections (OpenAI, 2026). It starts with ChatGPT Pro subscribers aged 18 and over in the United States, with businesses able to opt in through a new Commerce Partner Playbook (OpenAI, 2026; TechCrunch, 2026).

Why it matters. Agent shopping has been stuck on a trust problem: handing a card to software you cannot watch. A wallet that keeps the card hidden, demands approval every time, and still works with existing checkout systems turns a demo into something people might actually use.

Evidence status: Company announcement (November 13, 2026), independently reported by TechCrunch. Limits: limited rollout to US Pro subscribers; some sites may still block agent purchases; full delegation with spending limits is a future step, not today’s product.

Editor’s note

Every signal today arrives with its own check attached. A star’s companion is confirmed by X-rays, not by light alone. A peanut shot is tested against a placebo, and the benefit is measured again six months after the last dose. A liver drug’s full year of data passes peer review before anyone calls it progress. And a wallet for AI agents asks for approval on every purchase. The announcements are the news; the checks are what make them worth believing.

That’s the edition — four signals, every claim verified against its sources. Browse past briefs · tomorrow’s lands at 07:15.

The Progress Brief, by email

Useful progress, without the hype

The daily Positive Signals brief and the weekly deep dive, by email. Evidence-checked, concise, no doom.

Free. One daily email, one weekly email. Unsubscribe anytime.

References

  1. Altimmune, Inc. (2026, November 12). Altimmune announces publication of IMPACT Phase 2b 48-week data in MASH in The Lancet Gastroenterology & Hepatology. GlobeNewswire. https://www.globenewswire.com/news-release/2026/11/12/3401442/0/en/altimmune-announces-publication-of-impact-phase-2b-48-week-data-in-mash-in-the-lancet-gastroenterology-hepatology.html
  2. Aravax. (2026, November 12). Aravax announces positive results of Phase 2 clinical trial of PVX108, a novel immunotherapy for the treatment of peanut allergy. GlobeNewswire. https://www.globenewswire.com/news-release/2026/11/12/3401821/0/en/aravax-announces-positive-results-of-phase-2-clinical-trial-of-pvx108-a-novel-immunotherapy-for-the-treatment-of-peanut-allergy.html
  3. NASA. (2026, November 13). Outbursts from a massive star. https://www.nasa.gov/image-article/outbursts-from-a-massive-star/
  4. NDTV. (2026, November 13). NASA finds possible black hole behind mysterious repeated explosions of giant star. https://www.ndtv.com/science/nasa-finds-possible-black-hole-behind-mysterious-repeated-explosions-of-giant-star-12323787/amp/1
  5. OpenAI. (2026, November 13). Introducing ChatGPT Wallet. https://openai.com/index/introducing-chatgpt-wallet
  6. Pharmacally. (2026, November 13). Aravax reports improved peanut tolerance with monthly PVX108. https://pharmacally.com/aravax-pvx108-phase-2-peanut-allergy-trial-results/
  7. SnackSafely. (2026, November 12). New peanut allergy treatment shows lasting benefits six months after therapy ends. https://snacksafely.com/2026/11/new-peanut-allergy-treatment-shows-lasting-benefits-six-months-after-therapy-ends/
  8. TechCrunch. (2026, November 13). ChatGPT’s new Wallet lets AI agents shop and check out for you. https://techcrunch.com/2026/11/13/chatgpts-new-wallet-lets-ai-agents-shop-and-check-out-for-you/
  9. The Pharma Letter. (2026, November 12). Altimmune’s pemvidutide shows significant antifibrotic improvements in MASH trial. https://www.thepharmaletter.com/pharma-news/altimmunes-pemvidutide-shows-significant-antifibrotic-improvements-in-mash-trial

Similar Posts